A Phase 3 interventional study of Inhaled Insulin in Diabetes Mellitus, sponsored by Pfizer. Completed at 121 sites in 7 countries. Open to participants aged 35 Years to 80 Years. Per ClinicalTrials.gov, last updated 2008-04-17.
Sponsored by Pfizer · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 51 studies testing insulin in Diabetes Mellitus — 1 open to participants now, 2 under way, none of them phase 3. Insulin · Diabetes Mellitus.
Among the 51 studies testing insulin in Diabetes Mellitus, this one is the 3rd largest by enrollment of the 49 interventional ones that give a count, is one of 3 that started in 2005, is one of 11 in phase 3, and was the 3rd registered.
8,293 studies on the registry are indexed under Diabetes Mellitus; 1,072 are open to participants now.
Browse Diabetes Mellitus studies →1 of the 51 studies testing insulin in Diabetes Mellitus is open now, in 1 country. Recruiting first, the newest first:
Ohio State University · Sites in United States
Ages 18+ · Women only
By country, each count listing its studies:
No approval found in the FDA or EMA files read. How studies give it is on its page →
Of the 648 Diabetes Mellitus studies recruiting now, 357 (55%) set no upper age limit and 195 (30%) stop at 75 or younger; 88 take children under 18; 182 take healthy volunteers.
This study: 35 Years to 80 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
51 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 4 · Phase 2 12 · Phase 3 11 · Phase 4 12
First in 1994; this study’s year is marked. 3 started in 2005.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 1,100 is above the median of 80 across 6,025 interventional studies indexed under Diabetes Mellitus.
Median enrollment 74 across the 49 interventional studies. Of the 44 that completed or were terminated, 18 (41%) have results posted.
This tab as a report to print or save as PDF → With an account.
14 of 51 have an industry lead sponsor. The 10 most frequent:
Pfizer is the lead sponsor of 3,337 studies on the registry; 150 are open to participants now.
Of its 601 completed or terminated interventional studies of FDA-regulated products, 392 (65%) have results posted.
35 studies in Diabetes Mellitus by Pfizer: 2 open now, 3 under way, 3 of them phase 3. Of 30 finished, 15 (50%) have results posted.
Among the 35 studies in Diabetes Mellitus by Pfizer, this one is the 3rd largest by enrollment of the 30 interventional ones that give a count, is one of 3 that started in 2005, is one of 12 in phase 3, and was the 3rd registered.
Pfizer’s Diabetes Mellitus studies by the year they started, since 2000.
None of the studies under way reaches primary completion within a year.
Among the 51 studies testing insulin in Diabetes Mellitus, from their registry updates:
Nothing recorded among them since 2026-09-25.
Among Pfizer’s 35 in Diabetes Mellitus:
This tab as a report to print or save as PDF → With an account.
To assess the impact on glucose control by inhaled insulin in patients with type 2 diabetes who are not well controlled on 2 or more oral anti-diabetic agents
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.
COPD
Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Glycosylated hemoglobin
Percent of patients achieving good control of fasting glucose and lipids
Rate of hypoglycemia
Changes in body weight
Patient satisfaction
Safety based on adverse events reported and laboratory tests
Showing the first 100 of 121 sites across 7 countries. Choose a country and city above to see the rest.
The record gives a start of Apr 2005 and a completion of May 2007. It does not say whether these dates are actual or estimated.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Apr 2008. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Insulin